Skip to content

Imaging cerebral neuro-inflammation in acute and chronic cerebrovascular disease: a predictor of outcome and biomarker for guiding treatment (IN-CVD)

Imaging cerebral neuro-inflammation in acute and chronic cerebrovascular disease: a predictor of outcome and biomarker for guiding treatment (IN-CVD)

Status
Active, not recruiting
Phases
Phase 2
Study type
Observational
Source
ISRCTN
Registry ID
ISRCTN13797354
Enrollment
50
Registered
2015-07-20
Start date
2015-06-01
Completion date
Unknown
Last updated
2021-05-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Topic: Stroke

Interventions

The first year of the trial (phase 1) will be dedicated to assessing the technical feasibility, and comparing the new imaging agent ([18F]GE180) with an existing agent ([11C](R)PK11195). It is hoped t

Sponsors

The Christie NHS Foundation Trust
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Ischemic stroke in middle cerebral artery territory 2. Mild to moderate severity (Modified Rankin Scale score 2 or 3)

Exclusion criteria

Exclusion criteria: 1. Neurological diagnosis of neurodegenerative disease 2. Inability to understand study information and/or express willingness to consent to the study due to communication difficulties (patients that wish to consent but are unable to sign or mark the consent form due to mobility issues may give their consent orally in the presence of at least one witness, who must sign the consent form as evidence that the information was accurately explained to and understood by the subject and that consent was freely given) 3. History of brain surgery, brain tumour, neuroinflammatory or neurodegenerative disease 4. Severe uncontrolled systemic illness 5. Patients in whom carotid endarterectomy/carotid stenting is due to be carried out within three months of recruitment to the study 6. Treatment with other drugs known to influence microglial activation, e.g. minocycline or cortical steroids (2 weeks prior to date of stroke) 7. Pregnancy 8. Contraindications to MRI scanning

Design outcomes

Secondary

MeasureTime frame
Tolerability of the [18F]GE-180 scan as assessed by a patient-completed questionnaire asked at the end of the scans.

Primary

MeasureTime frame
Correlation between inflammation and the clinical outcome at 3 months after having a stroke. The clinical outcome is measured using the National Institutes of Health Stroke Scale Assessment (NIHSS), and the Modified Rankin Scale Assessment (mRS). These will be able to determine the extent of injury caused by the stroke.

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026